Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis

Seminars in Thrombosis and Hemostasis

Volumn 37, Issue 3, 2011, Pages 209-219

  Zamagni, Elena ^a   Brioli, Annamaria ^a   Tacchetti, Paola ^a   Zannetti, Beatrice ^a   Pantani, Lucia ^a   Cavo, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

deep vein thrombosis (DVT); lenalidomide; Multiple myeloma (MM); thalidomide; venous thromboembolism (VTE)

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; D DIMER; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FIBRIN; IMMUNOGLOBULIN; INTERLEUKIN 6; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PREDNISONE; PROCOAGULANT; THALIDOMIDE; VASCULOTROPIN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD VISCOSITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG MEGADOSE; ENDOTHELIUM CELL; FIBRINOLYSIS; GENETIC POLYMORPHISM; HIGH RISK PATIENT; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MULTIPLE MYELOMA; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTOPENIA; THROMBOSIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ACTIVATED PROTEIN C RESISTANCE; AGED; ANTICOAGULANTS; ASPIRIN; BORONIC ACIDS; DEXAMETHASONE; HUMANS; IMMUNOLOGIC FACTORS; INTERNATIONAL NORMALIZED RATIO; MULTIPLE MYELOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RISK FACTORS; THALIDOMIDE; THROMBOSIS; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 79953648712     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1273085     Document Type: Article

References (104)

1. Silverstein M D., Heit J A., Mohr D N., Petterson T M., O'Fallon W M., Melton L J. III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998 158 6 585-593 (Pubitemid 28144815)
2. Blom J W., Doggen C J., Osanto S, Rosendaal F R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005 293 6 715-722 (Pubitemid 40216041)
3. Caine G J., Stonelake P S., Lip G Y., Kehoe S T. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 2002 4 6 465-473 (Pubitemid 35417069)
4. Heit J A., O'Fallon W M., Petterson T M. et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002 162 11 1245-1248 (Pubitemid 34595030)
5. Eby C. Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol 2009 145 2 151-163
6. Falanga A, Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol 2009 27 29 4848-4857
7. Barlogie B, Jagannath S, Desikan K R. et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999 93 1 55-65 (Pubitemid 29019388)
8. Sallah S, Husain A, Wan J, Vos P, Nguyen N P. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol 2004 15 10 1490-1494 (Pubitemid 39409739)
9. Srkalovic G, Cameron M G., Rybicki L, Deitcher S R., Kattke-Marchant K, Hussein M A. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004 101 3 558-566 (Pubitemid 38970607)
10. Kristinsson S Y., Fears T R., Gridley G et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 2008 112 9 3582-3586
11. Kerr R, Stirling D, Ludlam C A. Interleukin 6 and haemostasis. Br J Haematol 2001 115 1 3-12 (Pubitemid 32995086)
12. Esmon C T. Does inflammation contribute to thrombotic events? Haemostasis 2000 30 Suppl 2 34-40 (Pubitemid 32234137)
13. Zangari M, Saghafifar F, Mehta P, Barlogie B, Fink L, Tricot G. The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost 2003 29 3 275-282
14. Gabriel D A., Smith L A., Folds J D., Davis L, Cancelosi S E. The influence of immunoglobulin (IgG) on the assembly of fibrin gels. J Lab Clin Med 1983 101 4 545-552 (Pubitemid 13119181)
15. Carr M E. Jr, Dent R M., Carr S L. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma. J Lab Clin Med 1996 128 1 83-88 (Pubitemid 26369173)
16. O'Kane M J., Wisdom G B., Desai Z R., Archbold G P. Inhibition of fibrin monomer polymerisation by myeloma immunoglobulin. J Clin Pathol 1994 47 3 266-268 (Pubitemid 24120693)
17. Yasin Z, Quick D, Thiagarajan P, Spoor D, Caraveo J, Palascak J. Light-chain paraproteins with lupus anticoagulant activity. Am J Hematol 1999 62 2 99-102 (Pubitemid 29463721)
18. Thiagarajan P, Dannenbring R, Matsuura K, Tramontano A, Gololobov G, Paul S. Monoclonal antibody light chain with prothrombinase activity. Biochemistry 2000 39 21 6459-6465 (Pubitemid 30347151)
19. Bokarewa M I., Blombäck M, Egberg N, Rosén S. A new variant of interaction between phospholipid antibodies and the protein C system. Blood Coagul Fibrinolysis 1994 5 1 37-41 (Pubitemid 24091320)
20. Zangari M, Elice F, Fink L, Tricot G. Hemostatic dysfunction in paraproteinemias and amyloidosis. Semin Thromb Hemost 2007 33 4 339-349 (Pubitemid 46878106)
21. Minnema M C., Fijnheer R, De Groot P G., Lokhorst H M. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003 1 3 445-449
22. Auwerda J J., Sonneveld P, de Maat M P., Leebeek F W. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica 2007 92 2 279-280 (Pubitemid 46852441)
23. Amrani D L. Regulation of fibrinogen biosynthesis: glucocorticoid and interleukin-6 control. Blood Coagul Fibrinolysis 1990 1 4-5 443-446
24. Elice F, Fink L, Tricot G, Barlogie B, Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006 134 4 399-405 (Pubitemid 44079553)
25. van Marion A M., Auwerda J J., Lisman T et al. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leuk Res 2008 32 7 1078-1084
26. Zangari M, Saghafifar F, Anaissie E et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 2002 13 3 187-192 (Pubitemid 35001883)
27. Sarig G, Michaeli Y, Lanir N, Brenner B, Haim N. Mechanism for acquired activated protein C resistance in cancer patients. J Thromb Haemost 2005 3 3 589-590 (Pubitemid 41632885)
28. Deitcher S R., Choueiri T, Srkalovic G, Hussein M A. Acquired activated protein C resistance in myeloma patients with venous thromboembolic events. Br J Haematol 2003 123 5 959 (Pubitemid 37533314)
29. Cavo M, Di Raimondo F, Zamagni E et al. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. J Clin Oncol 2009 27 30 5001-5007
30. Cini M, Zamagni E, Valdré L et al. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma patients: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. Eur J Haematol 2010 84 6 484-492
31. Rajkumar S V., Gertz M A., Lacy M Q. et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003 17 4 775-779 (Pubitemid 36519375)
32. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003 21 1 16-19
33. Barlogie B, Desikan R, Eddlemon P et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001 98 2 492-494
34. Neben K, Moehler T, Benner A et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002 8 11 3377-3382 (Pubitemid 35340711)
35. Schey S A., Cavenagh J, Johnson R, Child J A., Oakervee H, Jones R W. An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leuk Res 2003 27 10 909-914 (Pubitemid 36809087)
36. Tosi P, Zamagni E, Cellini C et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 2002 87 4 408-414 (Pubitemid 34297548)
37. Bennett C L., Schumock G T., Desai A A. et al. Thalidomide-associated deep vein thrombosis and pulmonary embolism. Am J Med 2002 113 7 603-606 (Pubitemid 35379916)
38. Attal M, Harousseau J L., Leyvraz S et al, Inter-Groupe Francophone du Myélome (IFM). Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006 108 10 3289-3294
39. Alexanian R, Weber D, Giralt S, Delasalle K. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann Oncol 2002 13 7 1116-1119
40. Sidra G, Williams C D., Russell N H., Zaman S, Myers B, Byrne J L. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica 2006 91 6 862-863 (Pubitemid 44014564)
41. Dimopoulos M A., Hamilos G, Zomas A et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J 2004 5 2 112-117 (Pubitemid 38519259)
42. Rajkumar S V., Hayman S, Gertz M A. et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002 20 21 4319-4323 (Pubitemid 35266292)
43. Rajkumar S V., Blood E, Vesole D, Fonseca R, Greipp P R., Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006 24 3 431-436 (Pubitemid 46630462)
44. Cavo M, Zamagni E, Cellini C et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 2002 100 6 2272-2273 (Pubitemid 35001274)
45. Cavo M, Zamagni E, Tosi P et al, Bologna 2002 study. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005 106 1 35-39 (Pubitemid 40967171)
46. Zangari M, Anaissie E, Barlogie B et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001 98 5 1614-1615
47. Osman K, Comenzo R, Rajkumar S V. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 2001 344 25 1951-1952 (Pubitemid 32553371)
48. Facon T, Mary J Y., Hulin C et al, Intergroupe Francophone du Myélome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007 370 9594 1209-1218 (Pubitemid 47516593)
49. Oakevree H, Baugh H, Boots M et al. A study of the safety and the efficacy of oral melphalan, prednisolone and thalidomide (MPT) in the treatment of multiple myeloma: a UK Myeloma Forum Pilot Study. Br J Haematol 2002 117 Suppl 1 66 (Abst)
50. Baz R, Li L, Kottke-Marchant K et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005 80 12 1568-1574 (Pubitemid 41747058)
51. Dimopoulos M A., Anagnostopoulos A, Terpos E et al, Greek Myeloma Study Group. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica 2006 91 2 252-254
52. Zangari M, Siegel E, Barlogie B et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002 100 4 1168-1171 (Pubitemid 34864267)
53. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003 121 5 768-771 (Pubitemid 36718193)
54. Lee C K., Barlogie B, Munshi N et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003 21 14 2732-2739 (Pubitemid 46606319)
55. Johnson D C., Corthals S, Ramos C et al. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood 2008 112 13 4924-4934
56. Pal R, Kennedy R, Mansour L R. et al. Cathepsin G, a potent platelets aggregation activator, is upregulated in multiple myeloma patients during treatment with lenalidomide (Revlimid). Blood 2007 110 738 (Abst)
57. Richardson P G., Blood E, Mitsiades C S. et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006 108 10 3458-3464
58. Zonder J A., Barlogie B, Durie B G., McCoy J, Crowley J, Hussein M A. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 2006 108 1 403-404 author reply 404
59. Dimopoulos M, Spencer A, Attal M et al, Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007 357 21 2123-2132 (Pubitemid 350146107)
60. Weber D M., Chen C, Niesvizky R et al, Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007 357 21 2133-2142 (Pubitemid 350146108)
61. Zangari M, Tricot G, Polavaram L et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol 2010 28 1 132-135
62. Rajkumar S V., Jacobus S, Callander N S. et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010 11 1 29-37
63. Rajkumar S V., Blood E. Lenalidomide and venous thromboembolism in multiple myeloma. N Engl J Med 2006 354 19 2079-2080
64. Menon S P., Rajkumar S V., Lacy M, Falco P, Palumbo A. Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer 2008 112 7 1522-1528 (Pubitemid 351441164)
65. Morgan G J., Schey S A., Wu P et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 2007 137 3 268-269 (Pubitemid 46537629)
66. Baz R, Walker E, Karam M A. et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 2006 17 12 1766-1771 (Pubitemid 44884050)
67. TM), adriamycin and dexamethasone chemotherapy (RAD) is safe and effective in treatment of relapsed multiple myeloma: first results of a German multicenter phase I/II trial. Blood 2006 108 408 (Abst)
68. Knight R, DeLap R J., Zeldis J B. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006 354 19 2079-2080
69. Galli M, Elice F, Crippa C, Comotti B, Rodeghiero F, Barbui T. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. Haematologica 2004 89 9 1141-1142 (Pubitemid 39295488)
70. Schey S A., Fields P, Bartlett J B. et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004 22 16 3269-3276 (Pubitemid 41103682)
71. Lonial S, Waller E K., Richardson P G. et al, SUMMIT/CREST Investigators. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005 106 12 3777-3784 (Pubitemid 41739012)
72. Zangari M, Guerreri J, Cavallo F et al. Coagulation related effect of bortezomib treatment in patients with relapsed or refractory multiple myeloma. Blood 2007 110 2733 (Abst)
73. Avcu F, Ural A U., Cetin T, Nevruz O. Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro. Thromb Res 2008 121 4 567-571 (Pubitemid 351174280)
74. Parry G C., Mackman N. Transcriptional regulation of tissue factor expression in human endothelial cells. Arterioscler Thromb Vasc Biol 1995 15 5 612-621
75. Hamaguchi E, Takamura T, Shimizu A, Nagai Y. Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB- dependent pathways in cultured human umbilical vein endothelial cells. J Pharmacol Exp Ther 2003 307 3 987-994 (Pubitemid 37494216)
76. Sohn R H., Deming C B., Johns D C. et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood 2005 105 10 3910-3917 (Pubitemid 40656136)
77. Lonial S, Richardson P G., San Miguel J et al. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol 2008 143 2 222-229
78. Jagannath S, Durie B GM, Wolf J L. et al. Long term follow up of patients treated with bortezomib alone and in combination with dexamethasone as frontline therapy for multiple myeloma. Blood 2006 108 238 (Abst)
79. Harousseau J L., Avet-Loiseau H, Attal M et al. High complete and very good partial response rates with bortezomib-dexamethasone as induction prior to ASCT in newly diagnosed patients with high-risk myeloma: results of the IFM2005-01 phase 3 trial. Blood 2009 114 353 (Abst)
80. Cavo M, Tacchetti P, Patriarca F et al. A phase III study of double autotransplantation incorporating bortezomib-thalidomide-dexamethasone (VTD) or thalidomide-dexamethasone (TD) for multiple myeloma: superior clinical outcomes with VTD compared to TD. Blood 2009 114 351 (Abst)
81. Zangari M, Barlogie B, Burns M J. et al. Velcade (V)-thalidome (T)-dexamethasone(D) for advanced and refractory multiple myeloma (MM): long term follow up of phase I-II trial UARK 2001-37: superior outcome in patients with normal cytogenetics and no prior T. Blood 2005 106 2552 (Abst)
82. Chanan-Khan A A., Padmanabhan S, Miller K C. et al. Final results of a phase II study of bortezomib (Velcade) in combination with liposomal doxorubicin (Doxil) and thalidomide (VDT) demonstrate a sustained high response in patients (pts) with relapsed (rel) or refractory (ref) multiple myeloma. Blood 2006 108 3539 (Abst)
83. Richardson P G., Jagannath S, Avigan D E. et al. Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase I trial. Blood 2006 108 405 (Abst)
84. Richardson P, Jagannath S, Raje N et al. Lenalidomide, bortezomib and dexamethasone (Rev/Vel/Dex) as front line therapy for patients with multiple myeloma (MM): preliminary results of a phase I/II study. Blood 2007 110 187 (Abst)
85. Richardson P, Jagannath S, Raje N et al. Lenalidomide, bortezomib and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): preliminary results of a phase II study. Blood 2007 110 2714 (Abst)
86. Terpos E, Anagnostopoulos A, Heath D et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) is an effective regimen for relapsed/refractory myeloma and reduces serum levels of Dickkopf-1, RANKL, MIP-1-alpha and angiogenic cytokines. Blood 2006 108 3541 (Abst)
87. Ciolli S, Leoni F, Casini C, Breschi C, Bosi A. Liposomal doxorubicin increases antitumor efficacy of low dose bortezomib, thalidomide and dexamethasone therapy in advanced multiple myeloma. Haematologica 2007 92 94-95 (Abst)
88. Jagannath S, Bensinger B, Vescio R et al. A phase II study of bortezomib (Velcade), cyclophosphamide (Cytoxan), thalidomide (Thalomid) and dexamethasone as first line therapy for multiple myeloma. Blood 2007 110 188 (Abst)
89. Wang M, Giralt S, Delasalle K, Handy B, Alexanian R. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 2007 12 3 235-239 (Pubitemid 46930250)
90. Zamagni E, Valdrè L, Cini M et al. Thrombophilic alterations and risk of venous thromboembolism in newly diagnosed multiple myeloma patients treated with thalidomide and high dose dexamethasone. Haematologica 2008 93 s1 363
91. Zamagni E, Valdrè L, Palareti G, Cavo M. Prevention of VTE in multiple myeloma patients. Thromb Res 2007 120 Suppl 2 S133-S136 (Pubitemid 350101782)
92. Wang M, Weber D M., Delasalle K, Alexanian R. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol 2005 79 3 194-197 (Pubitemid 40967073)
93. Palumbo A, Bringhen S, Caravita T et al, Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006 367 9513 825-831 (Pubitemid 43363369)
94. Minnema M C., Breitkreutz I, Auwerda J J. et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004 18 12 2044-2046 (Pubitemid 40028434)
95. Offidani M, Corvatta L, Piersantelli M N. et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 2006 108 7 2159-2164 (Pubitemid 44497495)
96. Zangari M, Barlogie B, Anaissie E et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004 126 5 715-721 (Pubitemid 39221309)
97. Barlogie B, Tricot G, Anaissie E et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006 354 10 1021-1030 (Pubitemid 43357806)
98. Cavo M, Palumbo A, Bringhen S et al. A phase III study of enoxaparin versus low-dose of warfarin versus aspirin as thromboprophylaxis for patients with newly diagnosed multiple myeloma treated up-front with thalidomide- containing regimens. Blood 2008 112 3017 (Abst)
99. Palumbo A, Dimopoulos M A., Delforge M et al. Phase III study to determine the efficacy and safety of Lenalidomide in combination with Melphalan and Prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma. Blood 2009 114 613 (Abst)
100. Klein U, Kosely F, Hillengass J et al. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol 2009 88 1 67-71
101. Palumbo A, Rajkumar S V., Dimopoulos M A. et al, International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008 22 2 414-423 (Pubitemid 351255436)
102. Lyman G H., Khorana A A., Falanga A et al, American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007 25 34 5490-5505 (Pubitemid 350232226)
103. Rajkumar S V., Hayman S R., Lacy M Q. et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005 106 13 4050-4053 (Pubitemid 41775908)
104. Zangari M, Fink L M., Elice F, Zhan F, Adcock D M., Tricot G J. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 2009 27 29 4865-4873